title: [Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis].
abstract: Non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) are among the most common liver diseases. NAFLD with pure steatosis is considered benign. NASH, however, may progress to liver cirrhosis with risk of liver cancer. Therefore, it is important to search for treatment modalities for NASH. Because obesity and insulin resistance are risk factors for NASH, weight loss and exercise are considered mandatory, although limited data are in support. Presently, we focus on the prognosis of NAFLD and NASH and on pharmaceutical treatment, especially in the form of vitamin E and pioglitazone.
authors.affiliation: Medicinsk Afdeling V, Aarhus Universitetshospital, Nørrebrogade 44, 8000 Aarhus C, Denmark. saraheeb@rm.dk
authors.forename: Sara
authors.initials: S
authors.lastname: Heebøll
authors.forename: Konstantin
authors.initials: K
authors.lastname: Kazankov
authors.forename: Marianne Kjær
authors.initials: MK
authors.lastname: Poulsen
authors.forename: Hendrik
authors.initials: H
authors.lastname: Vilstrup
authors.forename: Henning
authors.initials: H
authors.lastname: Grønbæk
mesh_terms: D005234:Fatty Liver / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000209:etiology; D008113:Liver Neoplasms / Q000209:etiology; D000077205:Pioglitazone; D011379:Prognosis; D012307:Risk Factors; D045162:Thiazolidinediones / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D014810:Vitamin E; D000077205:Pioglitazone